Combinatorial PD-1 and TIGIT blockade can elicit responses in murine models of PDAC (43) and these findings will help to guide optimal approaches to target TIGIT–CD115/CD112 interactions in cancer therapy (58). The gene discussed is NECTIN2; the disease is cancer.